Cyclo (RGDyC) (TFA)
Cyclo (RGDyC) TFA is a cyclic pentapeptide with anti-angiogenic abilities. Cyclo (RGDyC) TFA can be combined with liposome delivery systems for research on ocular neovascular diseases and cancer[1][2].
Product Specifications
UNSPSC
12352209
Target
Others
Type
Peptides
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cyclo-rgdyc-tfa.html
Purity
95.68
Solubility
H2O
Smiles
OC(C(F)(F)F)=O.O=C([C@@H](NC(CNC([C@@H](NC([C@@H](NC1=O)CS)=O)CCCNC(N)=N)=O)=O)CC(O)=O)N[C@@H]1CC2=CC=C(C=C2)O.[x]
Molecular Formula
C24H34N8O8S.xC2HF3O2
Molecular Weight
594.64 (free base)
References & Citations
[1]Lu Y, et al. Aqueous synthesized near-infrared-emitting quantum dots for RGD-based in vivo active tumour targeting. Nanotechnology. 2013 Apr 5;24 (13) :135101.|[2]Tang M, et al. Photostable and Biocompatible Fluorescent Silicon Nanoparticles-Based Theranostic Probes for Simultaneous Imaging and Treatment of Ocular Neovascularization. Anal Chem. 2018 Jul 3;90 (13) :8188-8195.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
HA751031 100 µL
Caspase-8 (p18) Recombinant Rabbit monoclonal Antibody
Sign In for Pricing
View Details 
